[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335610-105":59,"doc-detail-335610-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anti-ovarian-cancer-migration-and-toxicity-characteristics-of-a-platinumiv-pro-drug-with-axial-hdac-inhibitor-ligands-in-zebrafish-models","Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models","","Ovarian cancer is a leading cause of cancer mortality, and cisplatin therapy is limited by acquired resistance that reduces DNA targeting and increases irreversible renal and auditory damage. Histone deacetylase (HDAC) upregulation is linked to a closed chromatin state that hinders cisplatin activity. Compound B, a platinum(IV) pro-drug bearing axial phenylbutyrate (PBA) HDAC inhibitor ligands, was evaluated in ovarian cancer cell lines and zebrafish embryo and transgenic models for comparative effects on toxicity and metastasis. In vivo, low-dose compound B produced similar or reduced general, auditory, and renal toxicity relative to cisplatin while decreasing cancer metastasis more at 0.6 µM.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anti-ovarian-cancer-migration-and-toxicity-characteristics-of-a-platinumiv-pro-drug-with-axial-hdac-inhibitor-ligands-in-zebrafish-models/335610/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anti-ovarian-cancer-migration-and-toxicity-characteristics-of-a-platinumiv-pro-drug-with-axial-hdac-inhibitor-ligands-in-zebrafish-models/335610.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cisplatin less effective over time in ovarian cancer treatment?","Question",{"text":112,"@type":113},"Ovarian cancer often develops resistance to cisplatin, which reduces DNA targeting and increases the need for higher dosing. Higher dosing is associated with irreversible kidney and auditory tissue damage.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is Compound B and what hypothesis guides its use?",{"text":117,"@type":113},"Compound B is a platinum(IV) complex with axial phenylbutyrate (PBA) HDAC inhibitor ligands attached to a cisplatin core. The study tests whether simultaneously inhibiting HDAC-mediated resistance and damaging DNA can improve efficacy, especially at lower doses.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the zebrafish results compare compound B with cisplatin in toxicity and metastasis?",{"text":121,"@type":113},"Lower doses of compound B (0.3 or 0.6 µM) produced similar or reduced general, auditory, and renal toxicity compared with cisplatin (2.0 µM). At 0.6 µM, compound B reduced cancer metastasis more than 2.0 µM cisplatin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335610,1790463067,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Investigational New Drugs (2024) 42:644–654  \n[https://doi.org/10.1007/s10637-024-01479-3](https://doi.org/10.1007/s10637-024-01479-3)  \nAnti‑ovarian cancer migration and toxicity characteristics of a platinum(IV) pro‑drug with axial HDAC inhibitor ligandsin zebrafish models  \nSalma Begum1 · Scheldon D. Irvin1 · Carol K. Cox1 · Zhouyang Huang2 · Justin J. Wilson2,3 · Jerry D. Monroe1 · Yann Gibert1  \nReceived: 24 June 2024 / Accepted: 4 October 2024 / Published online: 21 October 2024 © The Author(s) 2024  \nSummary  \nOvarian cancer is the fifth leading cause of cancer related death in the United States. Cisplatin is a platinum-based anti-cancer drug used against ovarian cancer that enters malignant cells and then damages DNA causing cell death. Typically, ovarian cancer cells become resistant to cisplatin making it necessary to increase subsequent dosage, which usually leads to sideeffects including irreversible damage to kidney and auditory system tissue. Ovarian cancer resistance is often associated with upregulation of histone deacetylase (HDAC) enzymes that cause DNA to adopt a closed configuration which reduces the ability of cisplatin to target and damage DNA. Compound B, a platinum(IV) complex with two axial phenylbutyrate (PBA) HDAC inhibitor ligands attached to a cisplatin core, can simultaneously inhibit HDAC activity and damage DNA causing decreased cancer cell viability in cisplatin-sensitive (A2780) and-resistant (A2780cis) ovarian cancer cell lines. However, compound B was not previously evaluated in vivo. As simultaneously inhibiting HDAC-mediated resistance with cisplatin treatment could potentiate the platinum drug’s effect, we first confirmed the anti-cancer effect of compound B in the A2780 and A2780cis cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide spectrophotometric assay. Then, we used zebrafish embryo and transgenic animal models to comparatively analyze the effect of cisplatin, compound B, and controls on general organismal, auditory, and renal system toxicity, and cancer metastasis. We found that lower dosages of compound B (0.3 or 0.6 µM) than of cisplatin (2.0 µM) could cause similar or decreased levels of general, auditory, and renal tissue toxicity, and at 0.6 µM, compound B reduces cancer metastasis more than 2.0 µM cisplatin.  \nKeywords Zebrafish · Platinum(IV) · HDAC inhibitor · Xenografts · Toxicity · Cisplatin efficacy  \nIntroduction  \nThe platinum(II) complex, cis-[Pt(NH3)2Cl2] (cisplatin), has been successfully used against several cancers including ovarian, testicular, bladder, breast, non-small cell lung cancer, head and neck, and glioblastomas [1] . Cisplatin’s  \n* Yann Gibert [ygibert@umc.edu](ygibert@umc.edu)  \n1 Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 State Street, Jackson, MS 39216, USA  \n2 Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853-1301, USA  \n3 Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA 93106-9510, USA  \nanti-cancer activity is due to its ability to enter into the nuclei of cells where it binds to and damages DNA causing activation of cell death pathways [2] . However, cisplatin treatment typically activates resistance mechanisms which necessitates increased dosage in subsequent treatments leading to permanent damage to renal and auditory cells [3, 4] . Platinum(IV) complexes with a platinum(II) core attached to functionalized axial ligands that are released upon cell entry and which can target specific cancer mechanisms have been proposed as a next-generation of chemotherapeutics [5] . Recently, researchers have synthesized several platinum(IV) complexes derived from cisplatin with various histone deacetylase (HDAC) inhibitor axial ligands and found that these compounds can exhibit higher anti-cancer activity than the platinum(II) drug including in cisplatinsensitive and-resistant ovarian cancer cell lin","cbCaifFQkxNAksb0","https://ap.wps.com/l/cbCaifFQkxNAksb0","pdf",1302773,11,"English","# Summary\n## Experimental approach and rationale\n## In vitro findings\n## In vivo toxicity and metastasis results\n# Keywords\n# Introduction\n## Cisplatin resistance and HDAC-mediated chromatin effects\n## Platinum(IV) pro-drugs and axial HDAC inhibition\n## Zebrafish models for toxicity and metastasis","[{\"question\":\"Why is cisplatin less effective over time in ovarian cancer treatment?\",\"answer\":\"Ovarian cancer often develops resistance to cisplatin, which reduces DNA targeting and increases the need for higher dosing. Higher dosing is associated with irreversible kidney and auditory tissue damage.\"},{\"question\":\"What is Compound B and what hypothesis guides its use?\",\"answer\":\"Compound B is a platinum(IV) complex with axial phenylbutyrate (PBA) HDAC inhibitor ligands attached to a cisplatin core. The study tests whether simultaneously inhibiting HDAC-mediated resistance and damaging DNA can improve efficacy, especially at lower doses.\"},{\"question\":\"How did the zebrafish results compare compound B with cisplatin in toxicity and metastasis?\",\"answer\":\"Lower doses of compound B (0.3 or 0.6 µM) produced similar or reduced general, auditory, and renal toxicity compared with cisplatin (2.0 µM). At 0.6 µM, compound B reduced cancer metastasis more than 2.0 µM cisplatin.\"}]","Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models | PDF",1790011606,28]